Worldwide Study Finder

Loading registry information…

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

8 matching registry records; showing 8 on this page, newest registry updates first. Search checked 2026-10-07 17:19 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 1RecruitingINTERVENTIONAL

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

ClinicalTrials.gov · NCT07693426 · Registry updated: 2026-07-30

Condition / research focus: Adolescence Obesity
Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2026-07-16. Completion: 2027-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Efsubaglutide Alfa 5 mg QW (drug)
Efsubaglutide Alfa 10 mg QW (drug)
Efsubaglutide Alfa 20 mg QW (drug)
Efsubaglutide Alfa placebo (drug)

Where the study takes place — 5 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Beijing, Beijing Municipality, China

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Phase 2 / Phase 3Active, not recruitingINTERVENTIONAL

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

ClinicalTrials.gov · NCT06921486 · Registry updated: 2026-01-30

Condition / research focus: Obesity and Overweight
Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2025-03-31. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Phase IIb：Efsubaglutide Alfa 5 mg QW (drug)
Phase IIb：Efsubaglutide Alfa 10 mg QW (drug)
Phase IIb：Efsubaglutide Alfa 20 mg QW (drug)
Phase IIb：Efsubaglutide Alfa 20 mg Q2W (drug)
Phase IIb：Placebo (drug)
Phase III：Recommended Phase 3 Dose High Dose (drug)
Phase III：Recommended Phase 3 Dose Low Dose (drug)
Phase III：Placebo (drug)

Where the study takes place — 41 listed sites

Beijing Friendship Hospital, Capital Medical University
Beijing, China
Site recruitment: Not reported
Beijing Tsinghua Changgung Hospital
Beijing, China
Site recruitment: Not reported
Peking University First Hospital
Beijing, China
Site recruitment: Not reported
Changzhou First People's Hospital
Changzhou, China
Site recruitment: Not reported
Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital
Chengdu, China
Site recruitment: Not reported
Nanfang Hospital Southern Medical University
Guangzhou, China
Site recruitment: Not reported
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Site recruitment: Not reported
The First Affiliateo Hospital of Jinan University
Guangzhou, China
Site recruitment: Not reported
Zhujiang Hospital of Southern Medical University
Guangzhusi, China
Site recruitment: Not reported
The First People'S Hospital of Zunyi
Guizhou, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Site recruitment: Not reported
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, China
Site recruitment: Not reported
Anhui Provincial Hospital
Hefei, China
Site recruitment: Not reported
The First Affiliated Hospital of Henan University of Science and Technology
Henan, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanyang Medical College
Henan, China
Site recruitment: Not reported
Pingxiang People's Hospital
Jiangxi, China
Site recruitment: Not reported
Jincheng General Hospital
Jincheng, China
Site recruitment: Not reported
The Third Affiliated Hospital
Jinzhou, China
Site recruitment: Not reported
The First People's Hospital of Yunnan Province
Kunming, China
Site recruitment: Not reported
Luan City People's Hospital
Lu'an, China
Site recruitment: Not reported
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Nanjing, China
Site recruitment: Not reported
Nan Jing First Hospital
Nanjing, China
Site recruitment: Not reported
The Second Hospital of Nanjing Medical University
Nanjing, China
Site recruitment: Not reported
The Affiliated Qingyuan Hospital ,Guangzhou Medical University（Qingyuan People's Hospital）
Qingyuan, China
Site recruitment: Not reported
The First Hospital of Qinhuangdao
Qinhuangdao, China
Site recruitment: Not reported
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Shandong, China
Site recruitment: Not reported
Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University
Shanghai, China
Site recruitment: Not reported
Shanghai General Hospital
Shanghai, China
Site recruitment: Not reported
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Site recruitment: Not reported
The First Hospital Of China Medical University
Shenyang, China
Site recruitment: Not reported
Shenzhen Second People's Hospital
Shenzhen, China
Site recruitment: Not reported
The First Hospital of Hebei Medical University
Shijiazhuang, China
Site recruitment: Not reported
The Second Hospital of Hebei Medical University
Shijiazhuang, China
Site recruitment: Not reported
Suzhou Municipal Hospital
Suzhou, China
Site recruitment: Not reported
The Second Affiliated Hospital of Soochow University
Suzhou, China
Site recruitment: Not reported
General Hospital of Tianjin Medical University
Tianjin, China
Site recruitment: Not reported
Tianjin Medical University Chu Hsien-I Memorial Hospital
Tianjin, China
Site recruitment: Not reported
Tenth People's Hospital Of Tongji University
Wuhan, China
Site recruitment: Not reported
Wuhan Third Hospital Tongren Hospital of Wuhan University
Wuhan, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi'an Jiao Tong University
Xianian, China
Site recruitment: Not reported
Yueyang Central Hospital
Yueyang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Worldwide Study Finder

Find a study

Registry search results

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Explore the world’s study registries

Worldwide

Africa

Americas

A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）

A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients

Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients

Asia

Middle East

Europe

Oceania